Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: HER2-positive Breast Cancer
Interventions: OTHER: RNA sequencing|OTHER: Transcriptome analysis|DRUG: Trastuzumab|DRUG: Chemotherapy
Sponsor: OmicsWay Corp.
Collaborators: Oncobox Ltd., Russia|Vitamed LLC, Russia|Republican Oncological Dispensary of Karelia Republic, Russia